Our study provides a new potential therapeutic target and theoretical basis for reversing GC resistance to PD-1 mAbs and suggests the possibility of predicting the likelihood of GC patients becoming resistant to PD-1 mAb therapy based on serum LGMN expression levels. This evidence concerns the gene PDCD1 and gastric cancer.